Literature DB >> 8143995

Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer.

G Francini1, R Petrioli, L Lorenzini, S Mancini, S Armenio, G Tanzini, S Marsili, A Aquino, G Marzocca, S Civitelli.   

Abstract

BACKGROUND/AIMS: Colon cancer is one of the major health problems in industrialized countries, and its incidence appears to be increasing. Surgical resectability is the most important prognostic determinant, although despite apparently curative surgery, recurrent tumors are common. Metastatic disease cannot be cured, and thus, there is a need for better adjuvant therapies.
METHODS: Two hundred and thirty-nine patients with surgically resected colon cancer in Dukes' stage B2 or C were randomly assigned to chemotherapy or observation alone to determine whether adjuvant chemotherapy could effectively reduce the rate of cancer recurrence. One hundred and twenty-one patients in stage B2 and 118 patients in stage C were enrolled in the study. Adjuvant treatment consisted of folinic acid 200 mg/m2, intravenously, plus 5-fluorouracil 400 mg/m2, intravenously, on days 1-5 every 4 weeks for 12 cycles.
RESULTS: In stage B2, no significant difference between the adjuvant arm and the observation arm was noted. In stage C, adjuvant chemotherapy produced an advantage over observation in terms of a reduction in cancer recurrence rate with prolongation of a disease-free interval (P = 0.0016) and an improvement in overall survival (P = 0.0025).
CONCLUSIONS: This study shows that folinic acid plus 5-fluorouracil adjuvant chemotherapy is effective in patients with surgically resected Dukes' stage C colon carcinoma.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8143995     DOI: 10.1016/0016-5085(94)90748-x

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  43 in total

Review 1.  The evidence for adjuvant treatment of elderly patients (age > or = 70) with stage III colon cancer is inconclusive.

Authors:  Kok-Yang Tan; Fumio Konishi; Koichi Suzuki
Journal:  Surg Today       Date:  2010-03-26       Impact factor: 2.549

Review 2.  Challenges in the management of stage II colon cancer.

Authors:  Efrat Dotan; Steven J Cohen
Journal:  Semin Oncol       Date:  2011-08       Impact factor: 4.929

Review 3.  Human antibodies in cancer and autoimmune disease.

Authors:  H J Ditzel
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

4.  Toxicity and effects of adjuvant therapy in colon cancer: results of the German prospective, controlled randomized multicenter trial FOGT-1.

Authors:  L Staib; K H Link; H G Beger
Journal:  J Gastrointest Surg       Date:  2001 May-Jun       Impact factor: 3.452

5.  Survival of untreated advanced colorectal cancer patients.

Authors:  G P Stathopoulos
Journal:  Oncol Lett       Date:  2011-05-13       Impact factor: 2.967

Review 6.  Adjuvant chemotherapy for colorectal cancer.

Authors:  Anne Demols; Jean-Luc Van Laethem
Journal:  Curr Gastroenterol Rep       Date:  2002-10

7.  Role of caspases in 5-FU and selenium-induced growth inhibition of colorectal cancer cells.

Authors:  Aye Aye Thant; Yanyuan Wu; Jane Lee; Dhruva Kumar Mishra; Heather Garcia; H Phillip Koeffler; Jaydutt V Vadgama
Journal:  Anticancer Res       Date:  2008 Nov-Dec       Impact factor: 2.480

Review 8.  Colon cancer: survival after curative surgery.

Authors:  K H Link; T A Sagban; M Mörschel; K Tischbirek; M Holtappels; V Apell; K Zayed; M Kornmann; L Staib
Journal:  Langenbecks Arch Surg       Date:  2004-09-28       Impact factor: 3.445

9.  Identification of objective pathological prognostic determinants and models of prognosis in Dukes' B colon cancer.

Authors:  V C Petersen; K J Baxter; S B Love; N A Shepherd
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

Review 10.  Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation.

Authors:  Chun Seng Lee; Elizabeth J Ryan; Glen A Doherty
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.